[go: up one dir, main page]

PE20071085A1 - COMPUESTOS 2-OXO-3-PIRRODINIL COMO INHIBIDORES DEL FACTOR Xa - Google Patents

COMPUESTOS 2-OXO-3-PIRRODINIL COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
PE20071085A1
PE20071085A1 PE2006001489A PE2006001489A PE20071085A1 PE 20071085 A1 PE20071085 A1 PE 20071085A1 PE 2006001489 A PE2006001489 A PE 2006001489A PE 2006001489 A PE2006001489 A PE 2006001489A PE 20071085 A1 PE20071085 A1 PE 20071085A1
Authority
PE
Peru
Prior art keywords
oxo
alkyl
compounds
acutes
benzazepin
Prior art date
Application number
PE2006001489A
Other languages
English (en)
Inventor
Laure Maica Camus
Reshma Manesh Chudasama
Caroline Jane Day
Deepali Deshmukh
John Gerald Gleason
John David Harling
Chao-Pin Lee
Paula Saklatvala
Stefan Senger
Sarah Mary Vallance
John Watson
Nigel Stephen Watson
Robert John Young
Barbara Yuan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0523951A external-priority patent/GB0523951D0/en
Priority claimed from GB0609900A external-priority patent/GB0609900D0/en
Priority claimed from GB0620155A external-priority patent/GB0620155D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20071085A1 publication Critical patent/PE20071085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS 2-OXO-3-PIRRODINIL DE FORMULA (I) EN DONDE R1 ES SELECCIONADO DE a), b), c), ENTRE OTROS, DONDE CADA ANILLO CONTIENE OPCIONALMENTE UN HETEROATOMO DE N ADICIONAL; Z ES UN SUSTITUYENTE HALOGENO OPCIONAL; alq ES ALQUILENO O ALQUENILENO; T ES S, O o NH; R2 ES H, ALQUILO(C1-C6), ALQUIL(C1-C3)-CONRaRb, ENTRE OTROS; UNO DE W, X E Y ES -N(R6)- Y LOS OTROS SON -CH(R7)-; R3, R4 Y R5 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C4) O HALOGENO; R6 ES H O ALQUILO(C1-C4); R7, R8, R9 SON INDEPENDIENTEMENTE H O ALQUILO(C1-C4). SON SELECCIONADOS: 6-CLORO-N-[(3S)-2-OXO-1-(2,3,4,5-TETRAHIDRO-1H-2-BENZAZEPIN-7-IL-3-PIRROLIDINIL]-2-NAFTALENOSULFONAMIDA, 3-CLORO-N-[(3S)-2-OXO-1-(2,3,4,5-TETRAHIDRO-1H-2-BENZAZEPIN-7-IL)-3-PIRROLIDINIL]-1H-INDOL-6-SULFONAMIDA, (E)-2-(5-CLORO-2-TIENIL)-N-[(3S)-2-OXO-1-(2,3,4,5-TETRAHIDRO-1H-2-BENZAZEPIN-7-IL)-3-PIRROLIDINIL]-ETENOSULFONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DEL FACTOR Xa Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES VASCULARES AGUDAS TALES COMO: SINDROMES CORONARIOS AGUDOS, EMBOLIA PULMONAR TROMBOSIS VENOSA PROFUNDA Y SUCESOS TROMBOEMBOLICOS
PE2006001489A 2005-11-24 2006-11-22 COMPUESTOS 2-OXO-3-PIRRODINIL COMO INHIBIDORES DEL FACTOR Xa PE20071085A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0523951A GB0523951D0 (en) 2005-11-24 2005-11-24 Compounds
GB0609900A GB0609900D0 (en) 2006-05-18 2006-05-18 Compounds
GB0620155A GB0620155D0 (en) 2006-10-11 2006-10-11 Compounds

Publications (1)

Publication Number Publication Date
PE20071085A1 true PE20071085A1 (es) 2007-12-16

Family

ID=38042812

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001489A PE20071085A1 (es) 2005-11-24 2006-11-22 COMPUESTOS 2-OXO-3-PIRRODINIL COMO INHIBIDORES DEL FACTOR Xa

Country Status (7)

Country Link
US (1) US20080306045A1 (es)
EP (1) EP1951712A2 (es)
JP (1) JP2009517351A (es)
AR (1) AR058221A1 (es)
PE (1) PE20071085A1 (es)
TW (1) TW200738694A (es)
WO (1) WO2007059952A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414449A4 (en) * 2001-05-22 2005-04-06 Bristol Myers Squibb Co FACTOR XA BICYCLIC INHIBITORS
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
GB0314299D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2007059952A2 (en) 2007-05-31
US20080306045A1 (en) 2008-12-11
EP1951712A2 (en) 2008-08-06
JP2009517351A (ja) 2009-04-30
WO2007059952A3 (en) 2007-08-09
AR058221A1 (es) 2008-01-23
TW200738694A (en) 2007-10-16

Similar Documents

Publication Publication Date Title
AR065439A1 (es) Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
PE20091307A1 (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
PE20221730A1 (es) Derivado de cicloalquilurea
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
PE20120330A1 (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20061120A1 (es) Compuesto de heteroarilo como inhibidores del receptor p2y1
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1

Legal Events

Date Code Title Description
FC Refusal